Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 3, 2025

Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

MFMengjiao FuChina Agricultural UniversityJQJingjing QuFirst Affiliated Hospital Zhejiang UniversityJZJianya ZhouFirst Affiliated Hospital Zhejiang University

Discussion

Loading...

Member takes

Implication

A retrospective study reports efficacy and safety of various PD-1 inhibitors in advanced squamous NSCLC, suggesting promising outcomes.

Key Points

  • The objective response rate (ORR) reached 48.1% and the disease control rate (DCR) was 87.4% in patients treated with PD-1 inhibitors.
  • Patients treated with pembrolizumab showed the highest ORR of 52.5% with a median overall survival (OS) of 26 months.
  • Immune-related adverse events (irAEs) were experienced by 36% of patients, with nephritis being the most common at 10%.
  • Serum IL-6 levels significantly predicted overall survival, with higher levels correlating to shorter survival (P = 0.021).

Cite This Study

Fu et al. (2025) studied this question.

synapsesocial.com/papers/689a0c7be6551bb0af8d06abhttps://doi.org/10.21203/rs.3.rs-7161891/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC2020 · 165 citations
  2. 2Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine2017 · 43 citations
  3. 3Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial2020 · 619 citations
  4. 4The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer2021 · 78 citations
  5. 5Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy2017 · 99 citations